---
layout: minimal-medicine
title: Lipegfilgrastim
---

# Lipegfilgrastim
### Generic Name
Lipegfilgrastim

### Usage
Lipegfilgrastim is primarily used to decrease the occurrence and duration of infections or related complications stemming from neutropenia (a low level of neutrophils, a type of white blood cell crucial for fighting infection). This reduction in infection risk is particularly important for patients undergoing cytotoxic chemotherapy (cancer treatment using drugs that kill rapidly dividing cells).  It's specifically indicated for use in patients receiving such chemotherapy, excluding those with chronic myeloid leukemia or myelodysplastic syndromes.

### Dosage

**Adults:**  For neutropenia caused by chemotherapy, the typical subcutaneous (under the skin) dose is 6 mg once per chemotherapy cycle.  This injection should be given at least 24 hours after the completion of the chemotherapy treatment.

**Children:** The safety and effectiveness of Lipegfilgrastim in children and adolescents under 18 have not been established.  It is not recommended for this age group.

**Dosage Adjustments:** The manufacturer's labeling doesn't specify dosage adjustments for individuals with hepatic (liver) or renal (kidney) impairment. However, it's generally believed that Lipegfilgrastim's pharmacokinetics (how the body processes the drug) aren't significantly affected by these conditions.


### Side Effects

**Common Side Effects:**

* Nausea
* Alopecia (hair loss)
* Erythema (redness of the skin)
* Neutropenia (low neutrophil count, paradoxically, though usually mild and transient)
* Anemia (low red blood cell count)
* Thrombocytopenia (low platelet count)
* Leukopenia (low white blood cell count)
* Asthenia (weakness or fatigue)
* Ostealgia (bone pain)
* Musculoskeletal pain


**Less Common, but Serious Side Effects:**

* Headache
* Dizziness
* Chest pain
* Diarrhea
* Vomiting
* Decreased appetite
* Stomatitis (mouth sores)
* Dysgeusia (altered taste)
* Upper abdominal pain
* Dermatological reactions
* Hypokalemia (low potassium levels)
* Hypophosphatemia (low phosphate levels)
* Weight loss
* Hyperkalemia (high potassium levels)
* Myalgia (muscle pain)
* Arthralgia (joint pain)
* Hemoptysis (coughing up blood)
* Allergic reactions
* Interstitial pneumonitis (inflammation of lung tissue)
* Acute respiratory distress syndrome (ARDS)
* Capillary leak syndrome (CLS)
* Splenomegaly (enlarged spleen)
* Splenic rupture


If you experience any adverse effects, particularly those listed as serious, consult your healthcare provider immediately.


### How it Works

Lipegfilgrastim is a colony-stimulating factor (CSF).  It stimulates the production, maturation, and activation of neutrophils in the bone marrow. This leads to an increase in the number of these infection-fighting cells in the bloodstream. Lipegfilgrastim also enhances neutrophil activity, improving their ability to migrate to infection sites and destroy pathogens.  Its pegylation (attachment of polyethylene glycol) gives it a longer duration of action compared to filgrastim (another G-CSF) due to reduced renal clearance.


### Precautions

* **Contraindications:** Lipegfilgrastim is contraindicated in patients with hypersensitivity to Lipegfilgrastim, other G-CSF products (e.g., lenograstim, pegfilgrastim, and filgrastim), or any component of the formulation.
* **Interactions:**  Antineoplastic agents (cancer drugs) may reduce Lipegfilgrastim's effectiveness.  Lipegfilgrastim should be administered at least 24 hours after completion of myelosuppressive cytotoxic chemotherapy.  Concurrent use with cyclophosphamide may increase the risk of pulmonary toxicity.
* **Warnings:** There is an increased risk of serious allergic reactions, hematologic effects (thrombocytopenia and leukocytosis), pulmonary effects (interstitial pneumonia and ARDS), capillary leak syndrome, hypokalemia, antibody development, aortitis, splenomegaly and splenic rupture, and glomerulonephritis.  Use cautiously in patients with conditions predisposing them to hypokalemia or those concurrently receiving drugs that induce thrombocytopenia.  Lipegfilgrastim may trigger a severe sickle-cell crisis in patients with sickle cell disease.  It should not be used in patients with myelodysplasia, secondary acute myeloid leukemia (AML), or chronic myelogenous leukemia.
* **Pregnancy and Lactation:** Lipegfilgrastim is categorized as Pregnancy Category B3.  Avoid use during pregnancy.  Breastfeeding is not recommended due to the unknown excretion of Lipegfilgrastim in breast milk.


### FAQs

**Q: How is Lipegfilgrastim administered?**
A: It's administered subcutaneously (under the skin) in the abdomen, upper arm, or thigh.

**Q: How should Lipegfilgrastim be stored?**
A: Refer to the specific storage instructions on the product label. Generally, it should be refrigerated.

**Q: What should I do if I miss a dose?**
A: Contact your healthcare provider for guidance.

**Q: Are there any specific dietary restrictions while taking Lipegfilgrastim?**
A:  There are no specific dietary restrictions, but a healthy diet is generally recommended.  Some formulations contain sorbitol, so patients with hereditary fructose intolerance should avoid them.

**Q: Can I take Lipegfilgrastim with other medications?**
A:  Inform your doctor about all other medications you are taking to avoid potential interactions.

**Q: How long does it take to see results from Lipegfilgrastim?**
A: The effect varies depending on the individual and the underlying condition.  Blood tests are used to monitor its effectiveness.

**Q:  What are the long-term effects of Lipegfilgrastim?**
A:  Long-term effects are not fully understood.  Regular monitoring by a healthcare provider is essential.  


**Disclaimer:** This information is intended for general knowledge and informational purposes only, and does not constitute medical advice.  Always consult with a healthcare professional for any health concerns or before making any decisions related to your health or treatment.
